09.06.2022

GMP Compliance Adviser Update No 3/2022

 

The following overview lists the topics covered with this Update:

Information

GMP in Practice

Chapter 2 Personnel

  • 2.E Function owners

Chapter 5 Pharmaceutical Water

  • 5.A Water qualities
  • 5.B Pharmaceutical Water Generation
  • 5.D Qualification of water supply systems

GMP Regulations

Chapter C EU Directives and Guidelines

  • C.7 Compilation of Union Procedures on Inspections and Exchange of Information
  • C.10 EU Directives on Medical Devices
  • C.10.2 Regulation (EU) 2017/746 on in vitro diagnostic medical devices (EU IVDR)

Chapter G GMP of other Regions

G.2 Canadian Regulations:

  • G.2.1 Good manufacturing practices guide for drug products (GUI-0001)
  • G.2.2 Annexes to GUI-0001
  • G.2.2.1 Annex 7 to the Good manufacturing practices guide for drug products – Selected non-prescription drugs (GUI-0066)

G.6 Australian Regulations:

  • G.6.3 Australian Code of Good Manufacturing Practice for human blood and blood components, human tissues and human cellular therapy products
  • G.6.4 GMP clearance guidance

GMP in Practice

Chapter 2 Personnel

2.E Function owners

To ensure the safety of medicinal products, legislators have transferred tasks and responsibilities to certain function owners. The individual prerequisites and areas of responsibility are described in the drug law.
The function owners include

  • The Qualified Person
  • Head of Production
  • Head of Quality Control
  • Qualified Person Responsible for Pharmacovigilance
  • Scientific Service in Charge of Information
  • Medical sales representatives

External consultants also play an increasingly important role and their qualifications must therefore also be checked.
Michael Hiob, PhD

Chapter 5 Pharmaceutical Water

5.A Water qualities

The European Pharmacopoeia (Ph. Eur.) and the American Pharmacopoeia (USP) describe requirements for purified water and water for injections (WFI). In addition, both pharmacopoeias describe further water qualities for special purposes.
Since 2017 the European Pharmacopoeia also permits the use of membrane systems for the production of WFI. Therefore, the water quality "highly purified water" was eliminated in supplement 9.7. Due to the fact that "HPW" can still be found in various marketing authorisation dossiers, this water quality is likely to be used in practice for even longer. In addition, there is still a need for discussion in industry as to how WFI can be produced exactly using cold processes. The regulatory situation is not clear.
Purified water is intended by the pharmacopoeia for the manufacture of preparations that do not have to be sterile or pyrogen-free. In addition, purified water is often used as a starting material for the production of water for injections.
Highly purified water was intended for the manufacture of preparations for which a high biological quality of the treated water is required, but water for injections was not required.
Water for injections is used for the preparation of medicinal products for parenteral use, the solvent of which is water (water for injections in bulk). It can also be used to dissolve or dilute substances or preparations for parenteral use (sterilised water for injections).
The quality of each type of water must be proven by a number of tests described in the monographs. Physical-chemical tests include the determination of conductivity, tests for certain ions and the determination of TOC. Microbiological monitoring is required for all water qualities.
There is no monograph for pharmaceutical steam in the European Pharmacopoeia. In contrast, the USP contains a monograph on pure steam.
Herbert Bendlin, PhD, Fritz Röder

5.B Pharmaceutical Water Generation

When generating pharmaceutical water, drinking water is pre-treated to remove substances that are not desired during further processing. The pre-treatment processes include filtration, chemical stabilisation, UV irradiation and softening of the water using ion exchange. The processes that are used depend on the initial quality of the feed water. This is determined by water analysis.
To produce Purified Water, different processes are combined in so-called treatment plants. Reverse osmosis is widely used to produce Purified Water and is often combined with electro-deionisation.
Furthermore, the generation of water for injections (WFI) is explained in this chapter. For WFI, distillation was for a long time the sole method of production.
Since April 2017, the new Ph. Eur. monograph has applied to water for injection, which also permits the production of WFI using membrane technology. As a result of this change, the monograph for Highly Purified Water (HPW) was removed from the Ph. Eur. in April 2019. The advantages and possible risks of cold WFI production using membrane technology are discussed in detail.
The functionality and potential application of different technologies such as ion exchange, reverse osmosis, electro-deionisation, ultrafiltration and the various technologies used during distillation are described in detail and evaluated based on their advantages and disadvantages.
Herbert Bendlin, PhD, Fritz Röder

5.D Qualification of water supply systems

The qualification of a water treatment system is extremely comprehensive. Not only the design qualification, installation qualification and operational qualification are controlled, but data is also collected over a 1-year period as part of the performance qualification. The water can be released for pharmaceutical production 4–8 weeks after starting the performance qualification, provided that the values meet the predefined requirements. Nevertheless, with view to commercial and patient risks, it is suggested to complete the second phase of the performance qualification prior to release of any product.
A comprehensive and meaningful risk analysis which also describes the acceptance criteria for testing is the basis for all qualification testing. As is customary during the qualification process, a qualification plan is created and released for each phase before testing is carried out. The tests are documented in test records. After the tests are carried out, a report is created for each phase and the test records are attached to it. The report is evaluated and approved. After successful completion of one qualification phase, the next phase can begin. Deviations that occur must be checked.
Warning and action limits are defined for the performance qualification (PQ). They can be determined in a number of different ways. The type and frequency of sampling is also important for the PQ. If possible, the withdrawal method used during sampling should be used (e. g. withdrawal using a hose).
Fritz Röder


GMP Regulations

Chapter C EU Directives and Guidelines

C.7 Compilation of Union Procedures on Inspections and Exchange of Information

On 22 April 2022, a corrected version of Revision 18 was published, considering that Directive 2003/94/EC was repealed in exchange for Directive (EU) 2017/1572 (for human medicinal products) and Commission Delegated Regulation (EU) 2017/1569 (for investigational medicinal products for human use).

C.10.2 Regulation (EU) 2017/746 on in vitro diagnostic medical devices (EU IVDR)

On 26 May 2022, the European IVDR (EU) 2017/746 (In vitro Device Regulation) entered into force. This is accompanied by various transitional periods and requirements.
With this date the following Directives ceased to apply:

  • Directive on Active Implantable Medical Devices 90/385/EEC (AIMD)
  • Directive on Medical Devices 93/42/EEC (MDD)
  • Directive on in vitro diagnostic medical devices 98/79/EC (IVDD).

The dates for the granted transition periods have been partially adjusted:

  • 25 May 2022 – 26 May 2025
    Certificates still issued under the IVDD can remain valid until 26 May 2025; however, all Class D devices placed on the market after 26 May 2025 must be fully compliant with the IVDR.
  • By 26 May 2026
    All Class C devices placed on the market after 26 May 2026 must be fully compliant with the IVDR.
  • 26 May 2027
    All class B devices and class A sterile devices placed on the market after 26 May 2027 must be fully compliant with the IVDR.
  • Continued without change from 26 May 2022
    All non-sterile class A devices placed on the market after 25 May 2022 must be fully compliant with the IVDR. All new devices placed on the market must comply with the IVDR.

Chapter G GMP of other Regions

G.2 Canadian Regulations

With the current update of the GMP Compliance Adviser we have reviewed and updated section G.2 on Canadian Regulations.

G.6 Australian Regulations

With the current update of the GMP Compliance Adviser we have reviewed and updated section G.6 on Australian Regulations.


Service

Do you have any questions regarding the content of the chapters or need additional information?
Simply use the AskOurExperts button in the upper toolbar. Our team of experts will be glad to help!


Interested in using the GMP Compliance Adviser?

More information & order: GMP Compliance Adviser